A detailed history of Deep Track Capital, LP transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Deep Track Capital, LP holds 15,272,172 shares of AUTL stock, worth $35 Million. This represents 2.04% of its overall portfolio holdings.

Number of Shares
15,272,172
Previous 15,272,172 -0.0%
Holding current value
$35 Million
Previous $53.1 Million 4.31%
% of portfolio
2.04%
Previous 1.74%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$5.39 - $7.29 $18.3 Million - $24.8 Million
3,402,875 Added 28.67%
15,272,172 $97.4 Million
Q4 2023

Feb 14, 2024

SELL
$2.13 - $6.63 $6.67 Million - $20.8 Million
-3,130,703 Reduced 20.87%
11,869,297 $76.4 Million
Q4 2022

Feb 14, 2023

BUY
$1.74 - $3.27 $26.1 Million - $49.1 Million
15,000,000 New
15,000,000 $28.5 Million
Q2 2022

Aug 12, 2022

SELL
$2.04 - $4.68 $780,420 - $1.79 Million
-382,559 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$3.52 - $5.46 $1.35 Million - $2.09 Million
382,559 New
382,559 $1.6 Million

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $208M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Deep Track Capital, LP Portfolio

Follow Deep Track Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deep Track Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Deep Track Capital, LP with notifications on news.